Steroid Withdrawal in Renal Transplant Patients on Triple Therapy with a Calcineurin Inhibitor and Mycophenolate Mofetil: A Meta-analysis of Randomized, Controlled Trials
- 27 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 78 (10) , 1548-1556
- https://doi.org/10.1097/01.tp.0000140969.43761.1f
Abstract
Two previous meta-analyses of randomized, controlled trials of steroid withdrawal after renal transplantation have shown significant increases in acute rejection (both analyses) and graft failure rates (the last analysis). A new examination of this topic including only randomized, controlled trials based on currently used, new, potent therapy with calcineurin inhibitors and mycophenolate mofetil (MMF), avoiding early trials with azathioprine, is justified. Steroid withdrawal in patients on triple therapy including a calcineurin inhibitor and MMF was assessed through meta-analysis of randomized, controlled trials in which intention-to-treat rates of acute rejection and renal allograft failure were established after steroid withdrawal or continuation. Six trials were included, four in patients receiving cyclosporine and two in patients receiving tacrolimus. The risk ratio (RR) for acute rejection was 2.28 (95% confidence interval [CI], 1.65–3.16; P<0.00001) and the pooled risk difference (RD) was 0.08 (95% CI, 0.05–0.11; P<0.001), indicating that the proportion of patients with acute rejection after prednisone withdrawal was significantly higher compared with controls. The RR for graft failure was 0.73 (95% CI, 0.42–1.28; P=0.27) and the RD was −0.01 (95% CI, −0.03–0.01; P=0.28), indicating that the proportion of patients with graft failure after withdrawal was not significantly different from that observed in controls. Total cholesterol was significantly lower after steroid withdrawal (weighted mean difference, −0.53 μM (95% CI, −0.70 to −0.36; P<0.0001). Renal allograft recipients on triple therapy with a calcineurin inhibitor, MMF, and steroids are at low but significant risk of acute rejection after steroid withdrawal but do not suffer an increased risk of early graft failure. It is necessary to extend controlled follow-up to confirm graft function stabilization.Keywords
This publication has 43 references indexed in Scilit:
- Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus.1Transplantation, 2003
- Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot studyTransplantation, 2002
- Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant RecipientsAmerican Journal of Transplantation, 2002
- A Successful Liver Transplantation for Refractory Hepatic Veno‐Occlusive Disease Originating from Cord Blood TransplantationAmerican Journal of Transplantation, 2002
- Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy: A Randomized, Prospective, Multicenter StudyJournal of the American Society of Nephrology, 2002
- DOUBLE-BLIND COMPARISON OF TWO CORTICOSTEROID REGIMENS PLUS MYCOPHENOLATE MOFETIL AND CYCLOSPORINE FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1Transplantation, 2000
- STEROID WITHDRAWAL IN MYCOPHENOLATE MOFETIL-TREATED RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- LONG-TERM CONSEQUENCES OF DIFFERENT IMMUNOSUPPRESSIVE REGIMENS FOR RENAL ALLOGRAFTSTransplantation, 1993
- A PROSPECTIVE RANDOMIZED TRIAL OF PREDNISONE VERSUS NO PREDNISONE MAINTENANCE THERAPY IN CYCLOSPORINE-TREATED AND AZATHIOPRINE-TREATED RENAL TRANSPLANT PATIENTSTransplantation, 1990